Search results for "Clinical-Trials"

showing 7 items of 7 documents

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted …

2013

Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients…

MaleCancer ResearchLymphomamedicine.medical_treatmentFollicular lymphomaCHOPGastroenterologyAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularNON-HODGKINS-LYMPHOMASAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine; Oncology; Cancer ResearchCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenFludarabineSurvival RateOncologyVincristineFemaleFLUDARABINECLINICAL-TRIALSVidarabinemedicine.drugAdultVincristinemedicine.medical_specialtyAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; VincristineInternal medicinemedicineHumansRITUXIMABSurvival rateCyclophosphamideRESPONSE CRITERIAAgedNeoplasm StagingChemotherapyMitoxantronebusiness.industryFollicularmedicine.diseasePHASE-IIISurgery1ST-LINE TREATMENTDoxorubicinPrednisoneMitoxantroneNeoplasm GradingbusinessFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study …

2020

Publisher's version (útgefin grein)

MaleLife expectancyDisability-Adjusted Life YearDiseasesDiseasecommunicable diseasesystematic analysisGlobal Burden of Disease0302 clinical medicine80 and overMedicine10. No inequalityChild11 Medical and Health SciencesinjuriesAged 80 and overeducation.field_of_studySjúkdómarDEMENTIAFALLSGeneral MedicineForvarnir3. Good healthChild PreschoolHumanGBDPopulation health03 medical and health sciencesSDG 3 - Good Health and Well-beingHumansGlobal Burden of Disease StudyeducationAgedSpatial AnalysisGlobal burdenDisabilityPreventionDISABILITYInfantSpatial AnalysiMortality rateGlobal Burden of Disease Diseases Injuries Systematic analysisPREVENTIONYears of potential life lostRisk factorsDisease studyGBD; communicable disease; injuries;ITC-ISI-JOURNAL-ARTICLELife expectancyRISK-FACTORSClinical MedicineRADemographyFötlunDánartíðniÁhættuþættir030204 cardiovascular system & hematologyRisk FactorsCause of DeathGlobal health030212 general & internal medicineMortality ratePopulation health1. No povertyDisability-Adjusted Life YearsPublic Health Global Health Social Medicine and EpidemiologyMiddle Aged3142 Public health care science environmental and occupational healthAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Cause of Death; Child; Child Preschool; Disability-Adjusted Life Years; Female; Global Burden of Disease; Humans; Infant; Infant Newborn; Male; Middle Aged; Risk Factors; Spatial Analysis; Young Adult/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsaFemaleCLINICAL-TRIALSAdultAdolescentPopulationGlobal healthSettore MED/01 - Statistica MedicadiseasesITC-HYBRIDYoung AdultHeilbrigðisvísindiAge DistributionGeneral & Internal MedicineMortalityPreschoolDisease burdenbusiness.industryRisk FactorKlinisk medicinInfant NewbornNewborn//purl.org/pe-repo/ocde/ford#3.02.00 [https]Folkhälsovetenskap global hälsa socialmedicin och epidemiologiÁverkarSystematic analysisNAbusiness
researchProduct

Health-related quality of life is a prognostic factor for survival in older patients after colorectal cancer diagnosis: A population-based study

2015

International audience; Background: Studies carried out in the context of clinical trials have shown a relationship between survival and health-related quality of life in colorectal cancer patients.Aims: We assessed the prognostic value of health-related quality of life at diagnosis and of its longitudinal evolution on survival in older colorectal cancer patients. Methods: All patients aged >= 65 years, diagnosed with new colorectal cancer between 2003 and 2005 and registered in the Digestive Cancer Registry of Burgundy were eligible. Patients were asked to complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 at inclusion, three, six …

MaleMultivariate analysisColorectal cancerAppetiteDefinitions0302 clinical medicineQuality of lifeSurveys and QuestionnairesCancer registries030212 general & internal medicineAged 80 and overRelative survivalHazard ratioGastroenterologyScoresPrognosis3. Good healthSurvival RateOncology030220 oncology & carcinogenesisColonic NeoplasmsFemalePerspectivesmedicine.medical_specialtyPredict survivalClinical-TrialsContext (language use)Prognostic factorsFeeding and Eating DisordersAssociation03 medical and health sciencesInternal medicinePatient report outcomemedicineHumansMortalitySurvival rateAgedHepatologyRectal Neoplasmsbusiness.industryElderly-patientsCancer[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseElderly patientsQuality of LifePhysical therapyEuropean-organizationbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observat…

2020

Abstract: Background The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) assesses quality of life (QOL) in patients with lung cancer and was the first EORTC module developed for use in international clinical trials. Since its publication in 1994, major treatment advances with possible effects on QOL have occurred. These changes called for an update of the module and its international psychometric validation. We aimed to investigate the scale structure and psychometric properties of the updated lung cancer module, QLQ-LC29, in patients with lung cancer. Methods This international, observational field study was done in…

Malemedicine.medical_specialtyPsychometricsPsychometrics10255 Clinic for Thoracic SurgeryQUESTIONNAIRE610 Medicine & health03 medical and health sciences0302 clinical medicineCronbach's alphaQuality of lifeCarcinoma Non-Small-Cell LungSurveys and QuestionnairesMedicine and Health SciencesmedicineHumans030212 general & internal medicineVALIDITYLung cancerAgedLanguagebusiness.industryQLQ-C30CancerMiddle Agedmedicine.diseaseSmall Cell Lung CarcinomaTRENDShumanitiesConfirmatory factor analysisClinical trialOncology030220 oncology & carcinogenesisQuality of LifePhysical therapyFemaleObservational study2730 OncologyHuman medicinebusinessCLINICAL-TRIALS
researchProduct

Five insights from the Global Burden of Disease Study 2019

2020

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD …

health care deliveryMaleHumans -- MalatiesOutcome Assessmentglobal healthDiseaseReviewinsights030204 cardiovascular system & hematologySocioeconomic FactorgeographyGlobal Burden of DiseaseNoncommunicable Diseasedisease burdenCarga Global de Enfermedades0302 clinical medicineRisk FactorsOutcome Assessment Health CareHealth careGlobal healthDelivery of health carehealth outcomesmiddle income countrybirth rate030212 general & internal medicineBirth Ratehealth outcomes health system responses economic developmentFactores de Riesgopublic healthhealth care costGeneral MedicineRisk factor (computing)humanities3. Good healthfemalepriority journalrisk factorhealth system responsesepidemiologyTERRITORIESpoliticsCLINICAL-TRIALSmedicine.medical_specialtyBirth Rate; Delivery of Health Care; Global Burden of Disease; Noncommunicable Diseases; Outcome Assessment Health Care; Risk Factors; Socioeconomic Factors; Wounds and Injuries; epidemiologyinjury2019195 COUNTRIESArticleGlobal Burden of Diseases health outcomes risk factors health system responsesHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencessocioeconomicsmedicineSYSTEMATIC ANALYSISHumansGlobal Burden of Disease StudyhumanEpidemiologiaNoncommunicable DiseasesDisease burdenActuarial sciencehigh income countrybusiness.industryRisk FactorWounds and InjuriePublic healthagingHealth careeconomicsNon-communicable diseasemedicine.diseaseSalut públicaeconomic developmentEnfermedadesnon communicable disease//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health CareRisk factorsSocioeconomic Factorspopulation growthLife expectancylife expectancyWounds and InjuriesNAPrestación de Atención de Saludglobal disease burdenbusinessDelivery of Health Carelow income country
researchProduct

Effect of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy : A systematic review and meta-analysis

2017

Background/aim: Deficiency of acetyl-L-carnitine (ALC) and L-carnitine (LC) appears to play a role in peripheral diabetic neuropathy, although the evidence in humans is still limited. We conducted a systematic review and meta-analysis investigating the effect of ALC on pain and electromyographic parameters in people with diabetic neuropathy. Methods: A literature search in major databases, without language restriction, was undertaken. Eligible studies were randomized controlled trials (RCTs) or pre-and post-test studies. The effect of ALC supplementation on pain perception and electromyographic parameters in patients with diabetic neuropathy was compared vs. a control group (RCTs). The effe…

medicine.medical_specialtyDiabetic neuropathyDiabetePlaceboNerve conduction velocitylaw.inventionRATS03 medical and health sciencesGLUTAMATE0302 clinical medicineRandomized controlled triallawDiabetes mellitusMedicineQUALITYMeta-analysi030212 general & internal medicineUlnar nerveAdverse effectbusiness.industryDiabetesNERVE GROWTH-FACTORPAINmedicine.diseaseAcetyl-L-carnitine3. Good healthSurgeryNeuropathyAcetyl-L-carnitine; Diabetes; Meta-analysis; Neuropathy; Gerontology; Geriatrics and GerontologyMeta-analysisPeripheral neuropathyAnesthesia3121 General medicine internal medicine and other clinical medicineGeriatrics and GerontologybusinessGerontology030217 neurology & neurosurgeryCLINICAL-TRIALS
researchProduct